Table 2.
Combinatorial anti-CMV drug assessment using the Bliss independence checkerboard assay.
| 95% Confidence Interval Synergy Volume [µM2%] b |
|||||
|---|---|---|---|---|---|
| Drug Combination | Cell Type/Virus | Replicates a | Positive | Negative | Drug Interaction Type |
| MBV + GCV | HFF/HCMV AD169 | 2 | 0.0 ± 0.0 | −397.9 ± 39.2 | strongly antagonistic |
| ABE + GCV | HFF/HCMV AD169 | 2 | 5.0 ± 7.0 | −76.4 ± 56.1 | additive |
| ABE + LDC4297 | HFF/HCMV AD169 | 2 | 389.8 ± 117.1 | − 4.5 ± 6.3 | strongly synergistic |
| ABE + MBV | HFF/HCMV AD169 | 2 | 0.1 ± 0.1 | − 67.7 ± 83.9 | additive |
| TF27 + GCV | HFF/HCMV AD169 | 2 | 20.4 ± 3.6 | − 19.6 ± 26.7 | additive |
| TF27 + LDC4297 | HFF/HCMV AD169 | 1 | 10.0 | −6.7 | additive |
| TF27 + LMV | HFF/HCMV AD169 | 1 | 61.1 | −22.3 | additive |
| MBV + LDC4297 | HFF/HCMV AD169 | 2 | 138.6 ± 0.8 | −1.5 ± 2.2 | strongly synergistic |
a Individual experimental replicates were performed with measurements in triplicate. b The synergy volume [µM2%] values defining the drug interaction type are in bold print. The types of drug interaction were set as follows: values below −100, strongly antagonistic; −100 to +50, additive; +50 to +100, moderately synergistic; above +100 strongly synergistic [57,58]. GCV, ganciclovir; LMV, letermovir.